Endogenous Catecholamines in Immune Cells: Discovery, Functions And Clinical Potential as Therapeutic Targets
Experimental Study Shows that Learned Immunosuppressive Placebo Responses Attenuate Disease Progression in a Rat Model of Arthritis
FDA Authorizes an Emergency Use for Bamlanivimab – an Investigational Monoclonal Antibody – for the Treatment of Mild to Moderate COVID-19
NIH begins the first large randomized controlled trial of the combination of interferon beta-1a and remdesivir for treating COVID-19
Donna Jackson Nakazawa and Her New Book, THE ANGEL AND THE ASSASSIN: The Tiny Brain Cell that Changed the Course of Medicine
The Cross-talk between the Dopaminergic System and Innate Immunity: An Evolving ConceptMarch 27, 2018
Aducanumab Shows Promise and Impressive Effects in Reducing Alzheimer’s Amyloid-β PlaquesOctober 5, 2016
New Evidence Suggests Targeting Neuroinflammation May Be One Key to Slowing Alzheimer’s DiseaseAugust 16, 2016
Microglia and TREM2 Microglia-Specific Gene May Exert a Protective Role in Alzheimer´s DiseaseMay 24, 2016
TLRs-Activated Microglia Polarizes γδ T Cells towards a Neurotoxic IL-17+ γδ T Cell Phenotype: Implications for Multiple Sclerosis, Stroke and Alzheimer´s DiseaseApril 16, 2016
Blocking IL-12 and IL-23 in APPPS1 Mouse Model Shows Promise as an Experimental Therapeutic Approach to Alzheimer’s DiseaseFebruary 13, 2015
Antibiotics through Effects on the Microbiota-Gut-Brain Axis and Inflammatory Monocytes May Reshape Brain Hippocampal NeurogenesisApril 18, 2017
New Evidence Linking Clusterin and Other Complement Proteins to Alzheimer’s Progression and PredictionSeptember 15, 2016
Interleukin-33 Reverses Cognitive Deficits in Alzheimer’s Mouse Model Showing Promise as a Therapeutic TargetApril 27, 2016
New Evidence that Stress May Increase the Risk of Developing Dementia and Alzheimer’s: the Einstein Aging StudyJanuary 12, 2016
